Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring

MT Newswires Live08-07

Emergent BioSolutions (EBS) shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.

The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.

Two analysts surveyed by FactSet expected a loss of $0.09.

Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.

Two analysts expected $177.5 million.

For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.

Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.

Price: 5.17, Change: -2.38, Percent Change: -31.50

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657965441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 03:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657965441","market":"hk","top_or_hot":-1,"title":"Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.</p><p>The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.</p><p>Two analysts surveyed by FactSet expected a loss of $0.09.</p><p>Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.</p><p>Two analysts expected $177.5 million.</p><p>For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.</p><p>Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.</p><p>Price: 5.17, Change: -2.38, Percent Change: -31.50</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-07 03:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.</p><p>The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.</p><p>Two analysts surveyed by FactSet expected a loss of $0.09.</p><p>Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.</p><p>Two analysts expected $177.5 million.</p><p>For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.</p><p>Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.</p><p>Price: 5.17, Change: -2.38, Percent Change: -31.50</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657965441","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657965441","pubTimestamp":1786043234,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.Two analysts surveyed by FactSet expected a loss of $0.09.Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.Two analysts expected $177.5 million.For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.Price: 5.17, Change: -2.38, Percent Change:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EBS":"Emergent Biosolutions","BK4583":"猴痘概念"},"translate_title":"2026 年指引下调、重组后，Emergent BioSolutions 股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1.5},"content_text":"Emergent BioSolutions (EBS) shares fell 31% in Thursday trading after the company cut its full-year guidance and announced an organizational restructuring plan.The company reported Q2 adjusted earnings late Wednesday of $0.60 per diluted share, up from $0.24 a year earlier.Two analysts surveyed by FactSet expected a loss of $0.09.Revenue for the quarter ended June 30 was $234.3 million, up from $140.9 million a year earlier.Two analysts expected $177.5 million.For 2026, the company lowered its revenue guidance to $645 million to $675 million from the prior forecast of $720 million to $760 million. Two analysts expect $693.1 million.Also, the company disclosed a restructuring plan, that will lead to reduction of approximately 90 roles, eliminate 21 positions that are currently vacant, and closure of its wet laboratories in Gaithersburg, Maryland. The company also plans to eliminate the role of chief medical officer, head of research and development.Price: 5.17, Change: -2.38, Percent Change: -31.50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657965441","isCrawlerRequest":true}